Cytokinetics, Incorporated
NASDAQ:CYTKBiotechnology
+$2.90 today
- Market cap
- $7.15B
- Beta
- 0.43
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$6.73
Volume 1.59M
Average 2.37M
CYTK Total Non-current Liabilities
All obligations due after more than one year.
Cytokinetics, IncorporatedNASDAQ: CYTK
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities rises 31.0% from a year ago
Total non-current liabilities stood at $1.92B at the end of Q2 FY2026, up 31.0% from a year earlier and up 0.8% from the prior quarter. Over 3 fiscal years it compounded at +21.9% a year.
Context
- Total non-current liabilities amounted to 99.6% of total assets at the end of Q2 FY2026, down 19.8 pp from a year earlier.
- Total non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +31.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.88B USD
- Year-over-year change
- +38.6%
- 4-year CAGR
- +37.6%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.88B | +38.6% |
| FY2024 | 2024-12-31 | 1.36B | +22.5% |
| FY2023 | 2023-12-31 | 1.11B | +6.7% |
| FY2022 | 2022-12-31 | 1.04B | +97.5% |
| FY2021 | 2021-12-31 | 525.6M | — |
Total Non-current Liabilities vs competitors
How CYTK compares with its peers on the latest reported figures
- CYTK's Jun 2026 total non-current liabilities of $1.92B is the highest of the 3 companies compared; the peer median is $24.23M.
- Its year-over-year change of +31.0% is the highest of 2, against a peer median of +16.3%.
- Total non-current liabilities amounts to 99.6% of total assets for CYTK, versus a peer median of 10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.92B | +31.0% | +21.9% | 99.6% | |
| Mar 2026 | $36.35M | — | — | 12.4% | |
| Mar 2026 | $12.1M | +16.3% | -10.1% | 9.0% | |
| — | — | — | — | — | |
| Peer median (excluding CYTK) | $24.23M | +16.3% | -10.1% | 10.7% | |
Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 112.67M | 65.58M | 113.02M | 94.86M | 122.52M |
| Short-term Investments | 358.97M | 717M | 501.8M | 981.16M | 759.7M |
| Net Receivables | 51.82M | 147K | 1.28M | 16.65M | 17.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 12.46M | 0 | 15.28M | 16.99M |
| Total Current Assets | 535.67M | 795.19M | 628.05M | 1.11B | 916.98M |
| Property, Plant & Equipment (Net) | 146.41M | 163.19M | 147.74M | 140.97M | 155.17M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 152.05M | 46.71M | 40.53M | 145.06M | 335.05M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 7.19M | 9.69M | 8M | 7.71M | 17.34M |
| Total Non-current Assets | 305.65M | 219.59M | 196.27M | 293.73M | 507.56M |
| Total Assets | 841.32M | 1.01B | 824.32M | 1.4B | 1.42B |
| Account Payables | 21.09M | 25.61M | 21.51M | 20.37M | 22.34M |
| Short-term Debt | 0 | 958K | 10.08M | 11.52M | 41.18M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 52.37M | 1.61M |
| Other Current Liabilities | 16.47M | 22.89M | 39.81M | 21.11M | 80.08M |
| Total Current Liabilities | 71.86M | 84.62M | 102.68M | 179.67M | 202.45M |
| Long-term Debt | 142.84M | 609.62M | 607.37M | 645.6M | 1.12B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 87M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 183.53M | 301.55M | 380.16M | 599.19M | 657.76M |
| Total Non-current Liabilities | 525.6M | 1.04B | 1.11B | 1.36B | 1.88B |
| Total Liabilities | 597.46M | 1.12B | 1.21B | 1.54B | 2.08B |
| Common Stock | 84K | 94K | 102K | 118K | 123K |
| Retained Earnings | (1.21B) | (1.59B) | (2.11B) | (2.7B) | (3.49B) |
| Accumulated OCI | (869K) | (3.59M) | (10K) | 2.4M | 630K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 243.86M | (107.9M) | (386.32M) | (135.37M) | (659.63M) |
| Total Debt | 269.93M | 750.3M | 755.77M | 788.68M | 1.28B |
| Net Debt | 157.26M | 684.72M | 642.75M | 693.82M | 1.16B |
Cytokinetics, Incorporated
NASDAQ:CYTK
Intrinsic Alpha fair value
Locked
Current Price
$51.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.